DK3636640T3 - Krystal af heterocyclidenacetamidderivat - Google Patents
Krystal af heterocyclidenacetamidderivat Download PDFInfo
- Publication number
- DK3636640T3 DK3636640T3 DK18810263.6T DK18810263T DK3636640T3 DK 3636640 T3 DK3636640 T3 DK 3636640T3 DK 18810263 T DK18810263 T DK 18810263T DK 3636640 T3 DK3636640 T3 DK 3636640T3
- Authority
- DK
- Denmark
- Prior art keywords
- heterocyclidenaaceta
- crystal
- mid
- derivative
- mid derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762512775P | 2017-05-31 | 2017-05-31 | |
| JP2017108017A JP6230743B1 (ja) | 2017-05-31 | 2017-05-31 | ヘテロシクリデンアセトアミド誘導体の結晶 |
| PCT/JP2018/020634 WO2018221543A1 (ja) | 2017-05-31 | 2018-05-30 | ヘテロシクリデンアセトアミド誘導体の結晶 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3636640T3 true DK3636640T3 (da) | 2022-12-19 |
Family
ID=60321089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18810263.6T DK3636640T3 (da) | 2017-05-31 | 2018-05-30 | Krystal af heterocyclidenacetamidderivat |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10208010B2 (da) |
| EP (1) | EP3636640B1 (da) |
| JP (1) | JP6230743B1 (da) |
| KR (1) | KR102576964B1 (da) |
| CN (1) | CN110831930B (da) |
| CA (1) | CA3059483A1 (da) |
| DK (1) | DK3636640T3 (da) |
| ES (1) | ES2934508T3 (da) |
| HU (1) | HUE061363T2 (da) |
| MX (1) | MX2019014216A (da) |
| PL (1) | PL3636640T3 (da) |
| PT (1) | PT3636640T (da) |
| WO (1) | WO2018221543A1 (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6230743B1 (ja) | 2017-05-31 | 2017-11-15 | 持田製薬株式会社 | ヘテロシクリデンアセトアミド誘導体の結晶 |
| US20220204475A1 (en) * | 2019-04-30 | 2022-06-30 | Beijing Tide Pharmaceutical Co., Ltd. | Solid form of diaminopyrimidine compound or hydrate thereof, preparation method therefor, and application thereof |
| EP4043014A4 (en) * | 2019-10-04 | 2023-10-11 | Senju Pharmaceutical Co., Ltd. | PHARMACEUTICAL MEDICINAL PRODUCT CONTAINING HETEROCYCLIDE ACETAMIDE DERIVATIVE |
| WO2022210784A1 (ja) | 2021-03-30 | 2022-10-06 | 千寿製薬株式会社 | ヘテロシクリデンアセトアミド誘導体含有懸濁液 |
| WO2024071348A1 (ja) * | 2022-09-29 | 2024-04-04 | 千寿製薬株式会社 | 滅菌処理したヘテロシクリデンアセトアミド誘導体含有懸濁液 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101136183B1 (ko) * | 2005-07-22 | 2012-04-17 | 모찌다 세이야쿠 가부시끼가이샤 | 신규 헤테로시클리덴 아세트아미드 유도체 |
| ZA200800959B (en) * | 2005-07-22 | 2009-10-28 | Mochida Pharmaceutical Company | Novel heterocyclidene acetamide derivative |
| JP2011201777A (ja) * | 2008-07-23 | 2011-10-13 | Mochida Pharmaceut Co Ltd | 光学活性なヘテロシクリデン−ｎ−アリールアセトアミド誘導体 |
| JP2017108017A (ja) | 2015-12-10 | 2017-06-15 | キヤノン株式会社 | レーザ装置、及びこれを用いた計測装置 |
| JP6230743B1 (ja) | 2017-05-31 | 2017-11-15 | 持田製薬株式会社 | ヘテロシクリデンアセトアミド誘導体の結晶 |
-
2017
- 2017-05-31 JP JP2017108017A patent/JP6230743B1/ja active Active
-
2018
- 2018-05-30 KR KR1020197034846A patent/KR102576964B1/ko active IP Right Grant
- 2018-05-30 CA CA3059483A patent/CA3059483A1/en active Pending
- 2018-05-30 HU HUE18810263A patent/HUE061363T2/hu unknown
- 2018-05-30 EP EP18810263.6A patent/EP3636640B1/en active Active
- 2018-05-30 WO PCT/JP2018/020634 patent/WO2018221543A1/ja active Application Filing
- 2018-05-30 US US15/993,082 patent/US10208010B2/en active Active
- 2018-05-30 PL PL18810263.6T patent/PL3636640T3/pl unknown
- 2018-05-30 ES ES18810263T patent/ES2934508T3/es active Active
- 2018-05-30 DK DK18810263.6T patent/DK3636640T3/da active
- 2018-05-30 PT PT188102636T patent/PT3636640T/pt unknown
- 2018-05-30 CN CN201880035532.5A patent/CN110831930B/zh active Active
- 2018-05-30 MX MX2019014216A patent/MX2019014216A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP6230743B1 (ja) | 2017-11-15 |
| CN110831930B (zh) | 2023-04-28 |
| US20180346436A1 (en) | 2018-12-06 |
| EP3636640A4 (en) | 2021-03-03 |
| EP3636640A1 (en) | 2020-04-15 |
| CA3059483A1 (en) | 2018-12-06 |
| US10208010B2 (en) | 2019-02-19 |
| PT3636640T (pt) | 2022-12-26 |
| WO2018221543A1 (ja) | 2018-12-06 |
| RU2019137598A3 (da) | 2021-07-07 |
| KR102576964B1 (ko) | 2023-09-11 |
| ES2934508T3 (es) | 2023-02-22 |
| CN110831930A (zh) | 2020-02-21 |
| EP3636640B1 (en) | 2022-11-30 |
| KR20200011943A (ko) | 2020-02-04 |
| MX2019014216A (es) | 2020-01-23 |
| HUE061363T2 (hu) | 2023-06-28 |
| JP2018203648A (ja) | 2018-12-27 |
| RU2019137598A (ru) | 2021-06-30 |
| PL3636640T3 (pl) | 2023-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3596042T3 (da) | Krystalformer af aminolipider | |
| DK3515600T3 (da) | Array af organoider | |
| DK3315610T3 (da) | Fremgangsmåde til fremstilling af fucosylerede oligosaccharider | |
| DK3292134T3 (da) | Metode til dyrkning af akkermansia | |
| DK3331876T3 (da) | Modulators of ror-gamma | |
| DK3137169T3 (da) | Hæmmere af lysin-specifik demethylase-1 | |
| DK3509581T3 (da) | Formuleringer af (r)-2-amino-3-phenylpropylcarbamat | |
| DK3668851T3 (da) | Fremgangsmåde til fremstilling af thiocarbonater | |
| DK3325443T3 (da) | Fremgangsmåde til fremstilling af pridopidin | |
| DK3473621T3 (da) | Fremgangsmåde til fremstilling af diphenylmethan-derivat | |
| DK3317400T3 (da) | Fremgangsmåde til kryokonservering af tumorinfiltrerende lymfocytter | |
| DK3259349T3 (da) | Dehydrogenase-katalyseret fremstilling af FDCA | |
| DK3368683T3 (da) | Fremgangsmåde til kvantifikationen af pd-l1 | |
| DK3515990T3 (da) | Fremgangsmåde til fremstilling af lignocellulosematerialer | |
| DK3636640T3 (da) | Krystal af heterocyclidenacetamidderivat | |
| DK3457851T3 (da) | Derivater af sobetirom | |
| DK3279202T3 (da) | Krystal af 3,5-disubstitueret benzenalkynylforbindelse | |
| DK3390422T3 (da) | Krystalformer af lnt | |
| DK3280408T3 (da) | Fremgangsmåde til fremstilling af dicycloplatin | |
| DK3414367T3 (da) | Fosfordoteret siliciumenkeltkrystal | |
| DK3529236T3 (da) | Krystalformer af eravacyclin | |
| DK3418273T3 (da) | Derivater af flavagliner | |
| DK3678648T3 (da) | Fremgangsmåder til anvendelse af dipivefrin | |
| DK3678644T3 (da) | Formuleringer af copanlisib | |
| DK3519381T3 (da) | Fremgangsmåde til fremstilling af calciumdiglyceroxid |